N-甲基(3,4-亚甲二氧基苯甲酰)甲基-乙酰胺(SY-640)对化学致癌剂苯并芘与小鼠肝细胞核DNA共价结合的抑制作用

用小鼠肝细胞核制备和肝微粒体制备，研究了化合物ＳＹ６４０对致癌剂苯并芘（ＢＰ）损伤肝细胞核的保护作用及与Ｐ４５０的关系。结果表明，ＳＹ６４０可显著抑制３ＨＢＰ与小鼠肝细胞核的ＤＮＡ共价结合。ＳＹ６４０连续ｐｏ３ｄ，可显著诱导小鼠肝微粒体细胞色素Ｐ４５０含量及氨基比林脱甲基酶活性；给药１次２ｈ内却只抑制氨基比林脱甲基酶活性。体外温孵实验表明，ＳＹ６４０对小鼠肝微粒体氨基比林脱甲基酶活性也具有明显的抑制作用。差示光谱分析表明，ＳＹ６４０可与细胞色素Ｐ４５０形成络合物。提示该化合物对肝微粒体细胞色素Ｐ４５０酶系的影响与其对化学致癌剂ＢＰ所致肝细胞毒性的保护作用有关。     

灯盏细辛注射液对小鼠肝微粒体细胞色素P450含量的影响

目的:研究灯盏细辛注射液对小鼠肝微粒体细胞色素P450含量的影响。方法:小鼠分为空白对照组、阳性对照组(苯巴比妥钠80mg/kg,i.p.,共7d)、灯盏细辛注射液正常剂量组、高剂量组(10、30mg/kg,i.p.,共14d)。用紫外分光光度法测定细胞色素P450及其同工酶的活性。结果:灯盏细辛注射液两剂量组小鼠肝微粒体的蛋白含量和细胞色素P450含量较空白对照组增高,对肝重指数基本无影响;可抑制红霉素-N-脱甲基酶(ERD)的活性(P<0.01),而对氨基比林-N-脱甲基酶(AMD)基本无影响(P>0.05);苯巴比妥钠组肝重指数、蛋白含量和细胞色素P450含量与其他各组比较均升高(P<0.05),对氨基比林-N-脱甲基酶、红霉素-N-脱甲基酶活性均有诱导作用(P<0.01)。结论:灯盏细辛注射液对小鼠肝微粒体蛋白、细胞色素P450含量有一定影响,对CYP3A可能有抑制作用,对氨基比林-N-脱甲基酶活性基本无影响。     

妊娠大鼠肝微粒体药物代谢酶活性

<正> 为了解妊娠时肝脏对外源性化合物的生物转化能力是否发生改变,本文以苯胺羟化酶(ANH)及氨基比林N-脱甲基酶(AMD)活性为代表,系统研究了妊娠大鼠肝微粒体实行芳香化及N-脱甲基化作用的变化趋向. 成年未孕及妊娠12～14 d(中孕)和18～20 d(晚孕)♀Sprague-Dawley大鼠,按文献制备肝微粒体,测定药物代谢酶活性.结果表明,未孕大鼠肝微粒体细胞色素P450含量,b_5含量及NADPH-细胞色素c还原酶     

加替沙星和环丙沙星对大鼠肝细胞色素P450酶系的影响

目的 研究加替沙星和环丙沙星对大鼠肝微粒体细胞色素P450酶系的影响。方法 加替沙星和环丙沙星400 mg.kg-1灌胃给药大鼠,qd,7天后,用差速离心法制备大鼠肝微粒体,用Lowry法测定蛋白浓度,用分光光度计法检测6种肝微粒体细胞色素P450酶含量及活性,并用单因素方差分析进行统计。结果 加替沙星组的6种细胞色素P450酶的活性与空白对照组相比差异无统计学意义;而环丙沙星能抑制6种细胞色素P450酶中的b5、NADPH-CytC还原酶、氨基比林N-脱甲基酶、红霉素N-脱甲基酶和7-乙氧基香豆素脱烃酶的活性,对CYP450酶系有选择性抑制作用。结论 加替沙星对大鼠肝微粒体CYP450酶系无显著性影响,而环丙沙星对CYP450酶系有选择性抑制作用。     

加替沙星和环丙沙星对大鼠肝微粒体酶系的影响

目的研究加替沙星和环丙沙星对大鼠肝微粒体细胞色素P450酶系的影响.方法Wistar大鼠经加替沙星和环丙沙星400mg/kg灌胃给药,qd×7d后,应用差速离心法制备大鼠肝微粒体,采用Lowry法测定蛋白浓度,应用分光光度计法检测6种肝微粒体细胞色素P450酶含量及活性,并用单因素方差分析进行统计.结果加替沙星组中6种细胞色素P450酶测定结果与空白对照组相比差异无统计学意义,而环丙沙星能抑制6种细胞色素P450酶中的b5、NADPH-CytC还原酶、氨基比林N-脱甲基酶、红霉素N-脱甲基酶和7-乙氧基香豆素脱烃酶的活性,对CYP450酶系有选择性抑制作用.结论加替沙星对大鼠肝微粒体CYP450酶系无显著影响,而环丙沙星对CYP450酶系有选择性抑制作用.     

加替沙星和环丙沙星对大鼠肝微粒体酶系的影响

目的:研究加替沙星和环丙沙星对大鼠肝微粒体细胞色素P450酶系的影响.方法:Wistar大鼠经加替沙星和环丙沙星400mg/kg灌胃给药,qd&#215;7d后,应用差速离心法制备大鼠肝微粒体,采用Lowry法测定蛋白浓度,应用分光光度计法检测6种肝微粒体细胞色素P450酶含量及活性,并用单因素方差分析进行统计.结果:加替沙星组中6种细胞色素P450酶测定结果与空白对照组相比差异无统计学意义,而环丙沙星能抑制6种细胞色素P450酶中的b5、NADPH-CytC还原酶、氨基比林N-脱甲基酶、红霉素N-脱甲基酶和7-乙氧基香豆素脱烃酶的活性,对CYP450酶系有选择性抑制作用.结论:加替沙星对大鼠肝微粒体CYP450酶系无显著影响,而环丙沙星对CYP450酶系有选择性抑制作用.     

黄芩苷对小鼠肝细胞色素P450的选择性诱导

目的　观察黄芩苷对小鼠肝细胞色素P450及其亚家族的影响。方法　用紫外分光光度法分别测定小鼠肝微粒体细胞色素P450与b5含量及氨基比林N-脱甲基酶(ADM)、7-乙氧基香豆素O-脱乙基酶(ECD)、苯并芘羟化酶(AHH)活性。用蛋白印迹杂交技术鉴定细胞色素P450同功酶。结果　黄芩苷可使小鼠肝微粒体细胞色素P450含量显著增加,并使ADM,ECD及AHH 3种酶活力显著增强。对6种P450同功酶的鉴定结果显示,黄芩苷可选择性诱导1A1,2B1及2C11 3种同功酶,对细胞色素b5含量及3A2,2D1和2E1 3种同功酶无诱导作用。结论　黄芩苷对小鼠肝细胞色素P450有选择性诱导作用。     

年龄对大鼠肝脏生物转化功能及膜流动性的影响

通过与青年(3～4月)及中年(14月)组比较,研究了老年(24月)大鼠肝脏生物转化酶活性改变及膜流动性变化。结果表明,老年大鼠肝微粒体P-450含量、NADPH-细胞色素C还原酶活性无明显改变,但氨基比林N-脱甲基酶、苯胺羟化酶活性明显降低,且微粒体及胞浆GST、胞浆GSH-Px活性也明显下降;同时肝微粒体膜脂区流动性明显降低,膜Ch/PL值显著增大。研究提示,微粒体膜脂质环境及流动性变化与上述生物转化功能改变可能有一定的联系。     

对氨基二苯醚类似物抑制细胞色素P-450的定量构效关系

测定了一组对氨基二苯醚类似物延长小鼠戊巴比妥睡眠时间和体外抑制未经处理的小鼠肝微粒体催化氧化对硝基茴香醚脱甲基的活性。用逐步多元回归分析法导出了这些类似物体内和体外抑制细胞色素P-450(P-450)的活性与量化指数的定量构效关系(QSAR)。结果表明:对氨基二苯醚类似物体内和体外抑制P-450的活性均与最低未占据分子轨道能级(E_LUMO)、氨基氮原子的亲核超离域度(S_N(N))和醚氧原子的亲核超离域度(S_N(O))相关。这些类似物的代谢中间体(MI)与P-450形成P-450代谢中间体络合物(P-450-MI)可能是它们能够抑制P-450的主要原因。     

苯巴比妥诱导下大鼠肝微粒体药酶活性与膜流动性变化的相关性

本文用ANS和DPH为荧光探剂,研究苯巴比妥(PB)诱导下大鼠肝微粒体膜脂区流动性与膜药酶活性变化的相关性。结果表明,经PB诱导后在增加肝微粒体蛋白质含量,P-450含量及NADPH-细胞色素C还原酶等酶活性的同时,肝微粒体膜流动性明显增大,且膜深层流动性的增大与膜氨基比林N-脱甲基酶、细胞色素C还原酶活性增加有明显的直线正相关。膜胆固醇/碑脂比值明显降低。此结果提示,肝微粒体膜流动性的适当增大与PB增加单胺氧化酶系统活性之间可能存在着某种联系。     

Nitrite binding to cytochrome P-450 from liver microsomes of trout (Salmo gairdneri Rich.) and effects on two microsomal enzymes

Addition of nitrite to dithionite-reduced trout liver microsomes leads to the conversion of cytochrome P-450 into a cytochrome P-420-NO complex, as it does in mammalian microsomes. A loss in cytochrome P-450 and an inhibition of aminopyrine demethylase (AP) activity were observed in vitro at nitrite-concentrations found in the liver of trout exposed in vivo to this toxin. Nitrite had no effect on dimethylaniline monooxygenase (DMA), a cytochrome P-450-independent enzyme.     

In vitro studies on the metabolism and covalent binding of [14C]1,1-dichloroethylene by mouse liver, kidney and lung

The metabolism and covalent binding of 1,1-dichloro[1,2-14C]ethylene (DCE) to subcellular fractions of liver, kidney and lung of C57BL/6N mice have been investigated in vitro. Covalent binding was NADPH- and cytochrome P-450-dependent. The microsomal fraction bound more radiolabel than any other subcellular fraction, and the levels of covalent binding in cell fractions correlated well with their cytochrome P-450 content. Covalent binding by mouse liver and lung microsomes also reflected their cytochrome P-450 content. However, although mouse kidney microsomes contained twice as much total cytochrome P-450 as the lung, no detectable covalent binding of DCE-derived radioactivity occurred in kidney. Omission of NADPH, heat inactivation of microsomes, carbon monoxide, addition of SKF-525A, piperonyl butoxide or reduced glutathione (GSH), all inhibited (40-90%) covalent binding of radiolabel to liver and lung microsomes. The absence of O2 (incubation under N2) did not greatly affect the metabolism and covalent binding. Pretreatment of mice with various inducers, phenobarbital (PB), beta-naphthoflavone (beta-NF), pregnenolone 16 alpha-carbonitrile (PCN) and 3-methylcholanthrene (3-MC), evoked increases in total liver microsomal cytochrome P-450 content (2-fold) and corresponding increases in covalent binding (3-fold). However, microsomes from PCN-treated mice showed only a 50% increase in DCE binding. Kidney microsomes from control, PB-, and beta-NF-pretreated mice were incapable of covalent binding of radiolabel but those from PCN- and 3-MC-pretreated mice showed levels of binding similar to untreated mouse lung microsomes. It is proposed that the nephrotoxicity of DCE may be due to translocation of reactive metabolites from the liver to the kidney.     

Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450

The effects of nilutamide were studied first with human liver microsomes. At concentrations expected in the human liver (110 microM), nilutamide inhibited hexobarbital hydroxylase, benzphetamine N-demethylase, benzo(a)pyrene hydroxylase and 7-ethoxycoumarin O-deethylase activities by 85, 40, 35 and 25%, respectively. There was no in vitro inhibition of NADPH-cytochrome c reductase activity, no in vitro loss of CO-binding cytochrome P-450, and no spectral evidence for the in vitro formation of a possible cytochrome P-450Fe(II)-nitroso metabolite complex. Other studies were performed with mouse liver microsomes. Nilutamide (550 microM) did not significantly increase the consumption of NADPH by aerobic microsomes, and did not modify the kinetics for the reduction of cytochrome P-450 by NADPH-cytochrome P-450 reductase in an anaerobic system. Nilutamide (22 microM) produced either a type I or a type II binding spectrum. Kinetics for the inhibition of hexobarbital hydroxylase were consistent with competitive inhibition. A last series of experiments was performed after administration of nilutamide in mice. Thirty minutes after administration of doses (15 or 30 mumol.kg-1 i.p.) similar to those used in humans, the hexobarbital sleeping time was increased by 40 and 60%, respectively. There was no evidence, however, for the irreversible inactivation of microsomal enzymes since CO-binding cytochrome P-450 and monooxygenase activities remained unchanged in liver microsomes from mice killed 1 or 6 hr after administration of nilutamide (30 mumol.kg-1 i.p.). These results show that nilutamide inhibits hepatic cytochrome P-450 activity, and suggest that inhibition may actually occur after therapeutic doses of nilutamide in humans.     

Lack of in vitro and in vitro effects of fenbendazole on phase I and phase II biotransformation enzymes in rats, mice and chickens.

Intraperitoneal administration of 10 mg fenbendazole/kg bw daily for 5 d caused no significant alterations in the activities of hepatic microsomal drug-metabolizing enzymes viz aminopyrine N-demethylase, aniline hydroxylase and cytosolic glutathione S-transferase in rats, mice and chickens. Similarly no significant difference in the amount of microsomal cytochrome P-450 and NADPH-cytochrome c reductase was found between control and treated animals. In vitro incubation of fenbendazole with rat, mouse and chicken microsomes suggests that the drug neither binds to microsomal protein cytochrome P-450 nor inhibits the activities of aminopyrine N-demethylase and aniline hydroxylase. Similarly in vitro addition of fenbendazole to cytosolic glutathione S-transferase from the above species did not alter the activity of this enzyme. The results indicate that fenbendazole does not alter the activity of hepatic microsomal monooxygenase system significantly in rats, mice and chickens at a dosage level of 10 mg/kg body weight. In vitro studies also indicate that fenbendazole does not interact with the hepatic microsomal monooxygenase system, indicating it is not a substrate for cytochrome P-450-dependent monooxygenase system.     

Kinetic alterations in rat liver microsomal cholecalciferol 25-hydroxylase associated with phenobarbital administration

The kinetics of cholecalciferol 25-hydroxylase in vitamin D-depleted rat liver microsomes, before and after phenobarbital induction, were studied. Three days of pretreatment with phenobarbital altered significantly both the apparent K_m and the V_max of the hydroxylase. Untreated vitamin D-repleted rats had lower cytochrome P-450 content and aminopyrine demethylase activity than the vitamin D-depleted animals. Phenobarbital administration reversed this nutritional effect on aminopyrine demethylase but not on cytochrome P-450 content. Furthermore, vitamin D deficiency potentiated the phenobarbital inductive effect upon microsomal protein. No inhibition of aminopyrine demethylase could be elicited in the presence of cholecalciferol or 25-hydroxycholecalciferol either prior to or after phenobarbital treatment, suggesting that these two oxidases are different entities.     

Effect of spin traps in isolated rat hepatocytes and liver microsomes

Spin traps are increasingly employed in the detection of free radicals in biological systems, including liver microsomes and isolated hepatocytes. Two spin traps phenyl-t-butyl nitrone (PBN) and 4-pyridyl-l-oxide-t-butyl nitrone (4-POBN) have been tested for their effects on hepatocyte viability and mixed-function oxidase activity. High concentration of PBN but not of 4-POBN proved to moderately affect liver cell integrity, without interfering with intracellular ATP or cytochrome P-450 content. PBN also decreased hepatocyte GSH content, probably as the result of its metabolism to benzaldehyde. The two spin traps were found to inhibit aminopyrine demethylase and ethoxycoumarin deethylase activity in hepatocytes and microsomes. At low concentrations (1-5 mM) PBN enhanced aniline hydroxylase while high concentrations of the spin trap inhibited this activity. The inhibition of the monooxygenase system was not caused by damage of microsomal enzymes, but rather by competition with other substrates for the binding to the haemoprotein. The effects of spin traps on mixed function oxidase systems should be taken into account when evaluating the results of spin trapping experiments.     

Stimulation of microsomal drug oxidation activities by incorporation into microsomes of purified NADPH-cytochrome c (P-450) reductase.

The effects of addition of purified NADPH-cytochrome c (P-450) reductase on microsomal activities of aniline hydroxylation, p-phenetidine O-deethylation and ethylmorphine and aminopyrine N-demethylations were investigated utilizing microsomes from untreated, phenobarbital-treated and 3-methylcholanthrene-treated rats. The purified reductase was incorporated into microsomes. The drug oxidation activities were increased by the fortification of microsomes with the reductase while the extent of increase in the activities varied with the substrate and microsomes employed. The most pronounced enhancement was seen in p-phenetidine O-deethylation, followed by aniline hydroxylation and aminopyrine and ethylmorphine N-demethylations. The enhancement was more remarkable in microsomes from rats treated with 3-methylcholanthrene or phenobarbital. alpha-Naphthoflavone inhibited p-phenetidine O-deethylation activity markedly when the reductase was incorporated into microsomes, indicating that a larger amount of a species of cytochrome P-450 sensitive to the inhibitor was capable of participating in the oxidation of this substrate in the presence of the added reductase. One of the two Km values seen with higher concentrations of aniline or aminopyrine was altered by the fortification of microsomes with the purified NADPH cytochrome c (P-450) reductase. From these results, we propose that NADPH-cytochrome c (P-450) reductase transfers electrons to the selected one or two of multiple species of cytochrome P-450 more preferentially depending upon the substrate and the concentration of the substrate in microsomal membranes.     

Metabolism of 3-methylindole in human tissues.

Bioactivation of 3-methylindole (3MI), a highly selective pneumotoxin in goats, was investigated in human lung and liver tissues in order to provide information about the susceptibility of humans to 3MI toxicity. Human lung microsomes were prepared from eight organ transplantation donors and liver microsomes from one of the donors were utilized. The 3MI turnover rate with human lung microsomes was 0.23 +/- 0.06 nmol/mg/min, which was lower than the rate with the human liver microsomes (7.40 nmol/mg/min). The activities were NADPH dependent and inhibited by 1-aminobenzotriazole, a potent cytochrome P-450 suicide substrate inhibitor. Covalent binding of 3MI reactive intermediates to human tissues was determined by incubation of 14C-3MI and NADPH with human lung and liver microsomal proteins. Although human lung microsomes displayed measurable covalent binding activity (2.74 +/- 2.57 pmol/mg/min), the magnitude of this reaction was only 4% as large as that seen with human liver microsomes (62.02 pmol/mg/min). However, the covalent binding was protein dependent and also was inhibited by 1-aminobenzotriazole. Therefore, the bioactivation of 3MI to covalently binding intermediates is catalyzed by cytochrome P-450 in human pulmonary tissues. These activities were compared to those activities measured with tissues from goats. Proteins from goat and human pulmonary and hepatic microsomal incubations were incubated with radioactive 3MI, and radioactive proteins were analyzed by SDS-PAGE and HPLC and visualized by autoradiography and radiochromatography, respectively. The results showed that a 57-kDa protein was clearly the most prominently alkylated target associated with 3MI reactive intermediates.(ABSTRACT TRUNCATED AT 250 WORDS)     

Oxidation of thiobenzamide by the FAD-containing and cytochrome P-450-dependent monooxygenases of liver and lung microsomes

Two distinct microsomal pathways involved in the metabolism of thiobenzamide to thiobenzamide S-oxide have been identified and quantitated in the liver and lungs of mice and rats, using a highly inhibitory antibody against NADPH-cytochrome P-450 reductase. Approximately 50 and 65% of the oxidation in mouse and rat liver microsomes, respectively, was due to the FAD-containing monooxygenase, the remainder being catalyzed by cytochrome P-450. In the mouse lung, S-oxidation was predominantly via the FAD-containing monooxygenase while that in the rat lung was about 60% via the FAD-containing enzyme and 40% via cytochrome P-450. Cytochrome P-450-dependent S-oxidation of thiobenzamide was induced in the liver by treatment of mice with phenobarbital and slightly increased by treatment with 3-methylcholanthrene, while in rat liver either of these treatments caused only a small increase in metabolism due to cytochrome P-450. Thermal inactivation of the FAD-containing monooxygenase left the cytochrome P-450 component essentially unchanged. Thermally treated microsomes had a pH activity profile characteristic of cytochrome P-450 and were less inhibited by methimazole and thiourea when compared to untreated microsomes. Female mouse liver microsomes had a much higher, and female rat liver microsomes a lower, ability to S-oxidize thiobenzamide when compared to the males.     

Stereoselective monooxygenation of carcinostatic 1-(2-chloroethyl)-3-(cyclohexyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea by purified cytochrome P-450 isozymes

Three highly purified forms of liver microsomal cytochrome P-450 (P-450a, P-450b and P-450c) from Aroclor 1254-treated rats catalyzed 1-(2-chloroethyl)-3-(cyclohexyl)-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU) monooxygenation in the presence of purified NADPH-cytochrome P-450 reductase, NADPH, and lipid. Differences in the regioselectivity of CCNU and MeCCNU monohydroxylation reactions by the cytochrome P-450 isozymes were observed. Cytochrome P-450-dependent monooxygenation of CCNU gave only alicyclic hydroxylation products, but monooxygenation of MeCCNU gave alicyclic hydroxylation products, an αhydroxylation product on the 2-chloroethyl moiety, and a trans-4-hydroxymethyl product. A high degree of stereoselectivity for hydroxylation of CCNU and MeCCNU at the cis-4 position of the cyclohexyl ring was demonstrated. All three cytochrome P-450 isozymes were stereoselective in primarily forming the metabolite cis-4-hydroxy-trans-4-Methyl-CCNU from MeCCNU. The principal metabolite of CCNU which resulted from cytochromes P-450a and P-450b catalysis was cis-4-hydroxy CCNU, whereas the principal metabolites from cytochrome P-450c catalysis were the trans-3-hydroxy and the cis-4-hydroxy isomers. Total amounts of CCNU and MeCCNU hydroxylation with cytochrome P-450b were twice that with hepatic microsomes from Aroclor 1254-treated rats. Catalysis with cytochromes P-450a and P-450c was substantially less effective than that observed with either cytochrome P-450b or hepatic microsomes from Aroclor 1254-treated rats.